Difference between revisions of "Enasidenib (Idhifa)"
Jump to navigation
Jump to search
m (→Also known as) |
|||
| Line 14: | Line 14: | ||
[[Category:Oral medications]] | [[Category:Oral medications]] | ||
[[Category:Chemotherapy]] | [[Category:Chemotherapy]] | ||
| − | [[Category:Mutation-specific | + | [[Category:Mutation-specific medications]] |
[[Category:Acute myeloid leukemia medications]] | [[Category:Acute myeloid leukemia medications]] | ||
Revision as of 02:07, 5 August 2017
Mechanism of action
From the NCI Drug Dictionary: An orally available inhibitor of isocitrate dehydrogenase type 2 (IDH2), with potential antineoplastic activity. Upon administration, enasidenib specifically inhibits IDH2 in the mitochondria, which inhibits the formation of 2-hydroxyglutarate (2HG).
Diseases for which it is used
History of changes in FDA indication
- 8/1/2017: Granted FDA regular approval "for the treatment of adult patients with relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test.
Also known as
AG-221, CC-90007